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Read the introductory editorial on pages 26–27 and the  
related commentary by Steven Lewis on pages 28–30.
The Chair (Mrs. Joy Smith (Kildonan—St. Paul, 
Conservative  Party  of  Canada)):  We  will  now 
proceed.
I would like to go, first of all, to Mr. Bernard Prigent 
of the Canadian Institutes of Health Research governing 
council.
You have 10 minutes for a presentation, sir, on what-
ever you like.
Dr. Bernard Prigent (Member, Canadian Insti-
tutes of Health Research Governing Council, As 
an Individual):  Thank you, Madam Chair.
I wish to thank you and your colleagues for providing 
me with the opportunity to outline my role and contri-
bution as a member of the governing council of the Can-
adian Institutes of Health Research.
Let  me  begin  by  sharing  with  you  my  experience 
and credentials, which are relevant and consistent with 
CIHR’s overall objectives and mandate.
[Translation]	 I received my general medical training 
in France. At the start of my career, I had to deal with the 
major clinical and public health problems experienced 
by immigrants settling in the suburbs of Paris.
My interest in global health issues stems from my in-
volvement in a medical mission to Cambodia, in a war zone 
where, among other threats, civilians suffered from the 
ravages of multi-resistant malaria. That experience led me 
to write my thesis on tropical medicine and public health.
I  also  worked  for  five  years  in  various  demanding 
clinical and hospital environments in France, Asia and 
Australasia.  The  diverse  nature  of  those  clinical  ex-
periences led me to discover emergency medicine, ob-
stetrics, but especially, for nearly two years, the role of 
district physician. That was in a tropical environment, in 
Samoa. There, as the only practitioner, I had to provide 
care and promote public heath to a rural population of 
20,000 inhabitants.
All those experiences formed me and made me always 
keep in mind the viewpoint and interest of the patient, 
even when my career strayed from clinical medicine to 
medicine in a pharmaceutical environment.
[English]  I  joined  the  pharmaceutical  industry  in 
1984,  working  for  the  international  medical  and  clin-
ical research operations of three major European phar-
maceutical companies before joining Pfizer in Canada 
in 1995. I have worked on the clinical development and 
commercialization of new medicines in a variety of thera-
peutic areas, including cardiology, respiratory medicine, 
infectious  diseases,  rheumatology,  urology,  neurology, 
and oncology. I was able to pioneer the conduct of pivotal 
studies more than 20 years ago in countries like Poland, 
Hungary, and Russia, and developed medical and clin-
ical capabilities in Africa and in the Middle East. 
My interest in the management of research and de-
velopment  led  me  to  complete  an  MBA  in  the  United 
Kingdom  at  the  Henley  Management  College,  where 
my main research was on the management of global re-
search and development organization. 
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oration between the public and the private sectors. Such 
activities have enabled me to become chair of the scien-
tific  committee  of  the  research  foundation  of  Canada’s 
Research-Based  Pharmaceutical  Companies;  a  member 
of the strategic advisory committee of the Centre of Ex-
cellence in Personalized Medicine; a board member of the 
Centre of Excellence in the Prevention of Organ Failure; 
chairman of the strategic orientation committee of the 
Québec  Consortium  for  Drug  Discovery;  a  member  of 
the national advisory board of the Canadian Dementia 
Knowledge Translation Network; and co-president of the 
research working group of Montréal InVivo. 
[Translation]  I believe that my international clinical ex-
perience and my contribution to developing new drugs 
and to their accessibility for patients will be useful on the 
governing council of the Canadian Institutes of Health 
Research. The CIHR recently launched its five-year stra-
tegic plan. In particular, that plan emphasizes the im-
portance of cooperation between the industry and the 
research community so that research work leads to im-
proved health products, technologies, tools and services.
More specifically, the plan sets out a commitment to 
launch a new flagship initiative in patient-based research 
that will enable Canada’s health system to more effect-
ively use research results to improve care and health.
[English]  In recent years we’ve seen some measure of 
success  in  patient-oriented  research,  most  notably  in 
cardiovascular care, critical care, stroke, and HIV. How-
ever, Canada is rapidly falling behind other industrial 
countries in terms of the capacity to carry out high-level, 
patient-oriented research. In Canada we have some of 
the best health researchers in the world. Where we are 
less successful is in moving health research results out of 
the laboratory and into hospitals and clinics where they 
can improve health outcomes. 
I believe my significant experience in clinical research 
and  multilateral  research  collaborations  across  the 
world involving industry and academic-based research 
can assist CIHR in developing solutions to remedy these 
shortcomings. 
[Translation]  As a member of the CIHR governing coun-
cil, I undertake to strictly observe the Conflict of Inter-
est Act, the Ethical Guidelines for Public Office Holders, 
the Guidelines for the Political Activities of Public Office 
Holders and the CIHR’s Policy on Conflict of Interest and 
Confidentiality in the Context of Merit, Relevance and 
Peer Review. As a new member of the governing council, 
I have received orientation from CIHR management per-
sonnel and have carefully read all documents.
In closing, I repeat to the committee my dedication 
and commitment to meeting the highest ethical stan-
dards in this position, as I have in all those I have held 
in the past.
[English]  I now welcome the opportunity to answer 
any questions you may have. Thank you.
The Chair (Mrs. Joy Smith (Kildonan—St. Paul, 
Conservative  Party  of  Canada)):  Thank  you  very 
much.
Now we’ll go to Mr. Beaudet.
[Translation]
Dr.  Alain  Beaudet  (President,  Canadian  Insti-
tutes of Health Research): 
Thank you, Madam Chair. I’m pleased to appear be-
fore you as part of the review of Dr. Prigent’s recent ap-
pointment to the CIHR governing council.
[English]  Let me tell you right at the outset how much 
CIHR’s governing council and I personally welcome and 
support this superb addition to our board. Dr. Prigent 
was appointed by Governor in Council because of his vast 
knowledge, his unique experience, and his keen under-
standing of the Canadian international health research 
landscape. Like all other council members, Dr. Prigent 
was appointed as an individual and not as a representa-
tive of his employer. 
[Translation]  The  mandate  of  the  CIHR’s  governing 
council is to oversee the agency’s orientation and man-
agement. It defines its strategic orientations, objectives 
and policies, and assesses its overall performance. It is 
important to emphasize that it is not the council’s re-
sponsibility to examine or approve funding applications. 
There is no doubt in my mind that Dr. Prigent’s appoint-
ment meets the criteria for the appointment of members 
to the governing council as set out in the Canadian Insti-
tutes of Health Research Act.
That act states that council members must meet the 
highest standards of scientific excellence and represent 
a range of relevant disciplines and communities. No one 
will doubt Dr. Prigent’s exceptional qualifications and 
experience in this regard.
[English]  Dr. Prigent is a distinguished international re-
searcher and vice-president of Pfizer Canada Inc. He is a 
member of the Canadian Society of Clinical Pharmacology 
and the Canadian Arthritis Network. He sits on the board 
and  chairs  the  Scientific  Advisory  Council  of  Rx&D’s 
Health  Research  Foundation,  and  he  co-chairs  the  re-
search committee of Montréal InVivo, a non-profit group 
of over 600 public and private organizations in Montreal 
that promotes scientific partnership and innovation. 
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ground in matters ranging from global health to research 
management, particularly a vast experience in innova-
tion and commercialization, thereby filling what the gov-
erning council had identified as a major expertise gap in 
its midst. His unique knowledge in this field will enable 
us to better fulfill our responsibilities with respect to the 
achievement of CIHR’s objectives, as stated in section 4 
of the CIHR Act:
  to  excel,  according  to  internationally  accepted 
standards of scientific excellence, in the creation of 
new  knowledge  and  its  translation  into  improved 
health for Canadians, more effective health services 
and  products,  and  a  strengthened  Canadian  health 
care system, by (i) encouraging innovation, facilitating 
the commercialization of health research in Canada 
and promoting economic development through health 
research in Canada;
[Translation]  Innovation and commercialization are key 
elements in the CIHR’s mandate for improving the health 
of Canadians and the effectiveness of our health system.
As you are aware, Canada ranks poorly in private sec-
tor research and development investment. In fact, in its 
last report card on innovation, the Conference Board of 
Canada gave the country a D for its innovation perform-
ance in the past three decades.
This unfulfilled need has been underscored in the Gov-
ernment of Canada’s National Science and Technology 
Strategy which, on this point, specifically recommends:
  As the government fills vacancies on the councils’ 
governing  bodies,  it  will  seek  out  more  business 
and community representation to ensure that the 
composition of granting council governing bodies 
reflects  Canada’s  broad  economic  and  national 
interests.
[English]  Up until now, this call had been heard by vir-
tually every single federal research agency except CIHR. 
Indeed, members from the biopharmaceutical sector sit 
on the boards of Genome Canada, the National Research 
Council, the Natural Sciences and Engineering Research 
Council, and the Canadian Foundation for Innovation. 
Several provincial health research organizations, in-
cluding the Manitoba Health Research Council and the 
Fonds  de  la  recherche  en  santé  du  Québec,  also  have 
members  from  the  biopharmaceutical  industry  sitting 
on their boards. Likewise, sister councils in other coun-
tries—for instance, the Medical Research Council in the 
U.K.—have board members from this sector. 
In all cases, these individuals have been appointed 
not as representatives of their employers but as unique 
individuals willing to share their knowledge and able to 
help build bridges between the private and public sectors 
for the common good. 
In closing, I would like to remind the committee that 
all governing council members must observe the Conflict 
of Interest Act, the ethical guidelines for public office 
holders, and the guidelines for the political activities of 
public office holders, as a condition of appointment. 
In addition, disclosure of conflict of interest is a stand-
ing item on governing council meeting agendas. 
[Translation]  I  am  deeply  convinced  that  Dr.  Prigent’s 
appointment will have no negative impact on the CIHR’s 
integrity.  Quite  the  contrary,  his  presence  will  be  of 
great assistance in carrying out our mission. Dr. Prigent 
shares CIHR’s vision and brings unique expertise to its 
implementation.
Thank you.
[English]
The Chair:  Thank you. 
We’ll now go to our seven-minute round of questions 
and answers, beginning with Dr. Bennett. 
Hon. Carolyn Bennett (St. Paul’s, Liberal Party):     
[…]  The ability and perception of being able to make the 
ethical declaration and the conflict of interest declara-
tion is the concern that I think needs to be addressed, if 
you wouldn’t mind.
Dr. Bernard Prigent  As I said in my presentation, 
there is a very strong framework that’s put in place to 
manage conflict of interest. But before we talk about the 
tools, I want to refer to the fact that you don’t leave in-
tegrity and standards of integrity when you move from a 
sector to another. The responsibility of individuals serv-
ing the governing council is to, first of all, be driven by 
standards of integrity, and I think that throughout my 
career I’ve demonstrated the highest integrity in every-
thing I’ve done.
Now, in terms of managing what is available in terms 
of managing the conflict of interest, there is clearly the 
Conflict of Interest Act, there are the ethical guidelines 
for public office holders and the guidelines for political 
activities. In addition, conflict of interest declarations 
have to be made in a preamble of any agenda of the gov-
erning council. Every member of the governing council 
may be in a position of conflict of interest. Conflict of 
interest does not belong just to one sector. Every one of 
us, as individuals...we’re all representing different insti-
tutions and we all have potential conflicts of interest. So 
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as defined by the act, and to have procedures, which are 
indeed put in place by CIHR.
The number of activities that I’ve mentioned to you 
follow  exactly  the  same  guidelines,  where  you  have 
around the table very often people representing private 
interests, public interests, government interests, and we 
all have to declare any conflict of interest before any de-
cision is made.
In addition, there is something that is very important 
to realize: the governing council does not make decisions 
on investment towards any institution or any projects. So 
the review of funding is not a mandate of the governing 
council. I think it’s very important for this committee to 
understand.
The Chair:  Thank you, Mr. Prigent.
We now go to Monsieur Malo.
[Translation]
Mr.  Luc  Malo  (Verchères—Les  Patriotes,  Bloc 
Québécois):  Thank  you  very  much,  Madam  Chair. 
Dr. Beaudet and Dr. Prigent, thank you for being with us 
this afternoon. […]
Dr. Beaudet, I’d like to ask you my next question in 
the  wake  of  Dr.  Prigent’s  answer  to  my  Liberal  Party 
colleague.
Dr. Prigent said that everyone around the governing 
council table has a certain interest since they all belong 
to various organizations. You said in your presentation 
that the members of the governing council do not ap-
prove grant applications.
Have certain members of previous governing coun-
cils recused themselves at times when the council sat? 
If so, in what context? Can you elaborate a little on that 
subject?
Dr. Alain Beaudet:  I can definitely do that.
First of all, I would like to go back to the question from 
your colleague Ms. Bennett.
In fact, they are all potentially in conflict of interest. 
There is a vice-president for research. Is he speaking for 
his university? Should we have former vice-presidents of 
research? There’s also a dean of faculty of medicine. Is he 
speaking on behalf of his faculty of medicine? Should we 
have former deans of faculties of medicine?
We want people who are in the thick of the subject 
because  health  research  changes  extremely  quickly. 
We  want  the  country’s  leaders,  people  who  absolutely 
and  completely  know  all  research  aspects,  both  basic 
research aspects, which you referred to, and more ap-
plied research aspects, commercialization aspects such 
as aspects of research on health services.
The important thing is to be able to have expertise 
around the table. We are clearly looking for varied ex-
pertise that enables us to respond more effectively to our 
mission as a whole.
More specifically, it is quite rare for members of the 
governing council to have to recuse themselves because 
we do not make financial decisions. Active researchers 
nevertheless do sit on the governing council, and they 
may at times feel uncomfortable in certain discussions.
For example, one council member is an active stem cell 
researcher. When we discussed ethical issues related to 
stem cell research, that member recused himself. This is 
a question not only of conflict of interest, but of apparent 
conflict of interest as well, to which we are very sensitive. 
We do not want to give the impression that we favour one 
player over another. We are very sensitive to that.
[English]
The Chair:   Thank you, Mr. Beaudet.
Now we’ll go to Ms. Wasylycia-Leis.
Ms.  Judy  Wasylycia-Leis  (Winnipeg  North, 
New  Democratic  Party):  Thank  you,  Madam 
Chairperson.
And thank you, Dr. Prigent and Dr. Beaudet, for being 
here.
I want to begin by saying, Dr. Prigent, that I have no 
doubts  about  your  professional  expertise,  your  integ-
rity, or your significant experience. This is really about 
whether  it  makes  sense  to  have  someone  who  is  cur-
rently a vice-president, or in any position with a major 
drug company, sitting on the governing council of the 
CIHR. I know you said the governing council doesn’t ac-
tually give out money. The governing council governs the 
CIHR, whose mandate is to make decisions about where 
to target money, what priority areas should be focused 
on, how we can increase the research capacity in this 
country, and how we can support a new generation of 
health researchers. So it is rather important.
My question to you and to Dr. Beaudet, who I believe 
submitted your name in the first place—
Dr. Alain Beaudet:  Correct.
Ms. Judy Wasylycia-Leis: —is how do we explain your 
position to all these scientists—and you’ve heard their 
names—who have brought forward big concerns when 
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would put a particular slant on a body that’s supposed to 
be absolutely independent in terms of health research?
Dr. Bernard Prigent:  The nomination of someone 
representing any sector does not touch on the mandate 
of  independence.  The  independence  is  there.  I  find  it 
hard to believe that the presence of one person from one 
sector could derail the mandate of the governing council.
Once again, I have been asked to sit on the governing 
council as a citizen and as someone who brings experi-
ence. And that experience can be brought to the service 
of the public good.
I tend to take my cues from the international environ-
ment. As I said, when you look at the Medical Research 
Council, the United Kingdom is paying a lot of attention 
to issues similar to those here. And they have this as a 
standard practice. If you look at the similar body in Aus-
tralia, it’s the same. If you’re looking at a similar organ-
ization in France, it’s the same.
So the principle, if you like.... And I fully share your 
concerns. But we cannot have a situation where, when it 
comes to thinking strategically about the health of Can-
adians, we’re creating some kind of intellectual apart-
heid, with some people not being asked to the table.
I find it extremely surprising. If there’s one thing I 
pay attention to, it’s the conflict of interest. I think it’s 
important.
If  you  go  into  a  private  research  institution  and  a 
public research institution, there is no difference. These 
people come from the same background. They have the 
same goals. They want to do good and they want to bring 
innovation to the service of patients. It’s important to 
take that into consideration when you’re looking at the 
appointment.
I understand the sensitivity, but it’s really important 
for Canada and for CIHR to move forward and tackle—
Ms.  Judy  Wasylycia-Leis:  I  think  what  folks  are 
saying is that there are other ways for CIHR to in fact tap 
into the private sector expertise, and there are advisory 
bodies, and there are other ways in which we can benefit 
from your expertise based in the commercial sector. But 
I think an appointment of this nature on the governing 
council tells folks that in fact we’re prepared to under-
mine the independence of the body and open up a pos-
sible trend in terms of commercialization on what should 
be absolutely neutral, independent bodies, particularly 
when it comes to drug companies— […]
I would specifically ask the question of the conflict 
of interest and what that means for the body, and what 
it means for the entire field, especially in terms of the 
context of Pfizer. Whether or not all of the mistakes that 
Pfizer made were in your time or not, your name is there 
in some of the most difficult cases. In fact, I think it’s 
probably fair to say that your name is associated and it’s 
tied to papers where there’s been a significant history of 
transgressions against the integrity of science. I think 
that has to be understood and therefore taken into ac-
count in terms of assessment.
The Chair:  […]  Perhaps you’d like to make a com-
ment on that.
Dr. Alain Beaudet:  First of all, I’d like to reiterate 
that Dr. Prigent is not representing Pfizer. Actually, if 
he was representing Pfizer, the outcry wouldn’t be from 
the community; it would be from all the pharmaceutical 
companies that would also want to have a representative. 
Dr.  Prigent  is  representing  himself.  He  is  bringing 
his unique expertise to the table. It’s an expertise, quite 
frankly, that I cannot believe was not there at CIHR pre-
viously. We’re talking about the sector that is the third 
largest investor in R and D in this country. We’re talking 
about a major player in health research, and we wouldn’t 
talk to them? We wouldn’t ensure that we align a vision?
I  think  we  have  to  start  doing  things  differently. 
I think we really have to first listen to each other and 
understand how Canada can do better on the world stage 
in terms of being truly competitive in health research. 
That’s what we’re talking about here. If we want to align 
our agendas, if we want to do that and as a country be 
competitive, we have to look at ways to work together 
with the private sector. I think we need to learn how to 
do that. Who better qualified than someone like Dr. Pri-
gent to help us do that better?
The Chair:  Thank you, Mr. Beaudet. 
We’ll now go to Dr. Carrie.
Mr. Colin Carrie (Oshawa, Conservative Party of 
Canada):  Thank you Madam Chair.
To follow up, Dr. Beaudet, you mentioned expertise. 
As you know, before I was the PS [parliamentary secre-
tary] to health, I was the PS to industry, and one of the 
biggest complaints I got was that there’s not enough real-
world experience. Government makes these programs 
and regulations without enough input from the private 
sector. You mentioned that this sector is huge in Can-
ada. Occasionally, government, though well meaning, is 
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novation, commercialization, and applied research.
That’s what we want to do as a country. We want to 
create good quality jobs; we want to stimulate the econ-
omy. You mentioned we were given a D. So there are 
some things that we need to do better. Internationally 
and in Canada, these types of appointments are noth-
ing new. We talked about the health research board in 
Ireland and what they’ve done. If we look at the amount 
of research and development that Ireland has seen over 
the last 20 years.... Dr. Prigent, you mentioned that Aus-
tralia, the United States, and the U.K. all have private 
representation. In Canada, even four provinces have the 
private sector involved. 
So my question to you, Dr. Beaudet, is what has been 
the experience in these countries around the world? Are 
these countries prisoner to the private sector agenda? 
How are they finding this type of expertise to have on 
their agencies?
Dr. Alain Beaudet:   First of all, I can only state what 
I know. I know for a fact that there’s a heavy presence in 
the U.K. on the board of MRC of the biopharmaceutical 
sector, and I must say that they are fairly successful at 
curbing the trend and doing things differently in terms 
of innovation and public-private partnership. I think it 
has certainly been a major plus in that country. 
I am also familiar with the CNRS in France, where 
there have also been, as you know, members on the board 
from the biopharmaceutical sector. There again, I can see 
only positive aspects. It’s obvious that I would not have 
recommended Dr. Prigent to Minister Aglukkaq if I didn’t 
feel it was an area where I thought we needed to do better. 
As you know very well, we are in the midst of an eco-
nomic downturn. I happen to believe that the way we’re 
going to get out of it for good is through research and 
innovation, and it’s not the public sector alone that’s go-
ing to do it. It’s the public sector and the private sector, 
and we have to work together. We have to understand 
what the needs of the private sector are. The private sec-
tor must understand where the public sector is going. We 
have to join our efforts. As Dr. Prigent mentioned, when I 
was head of the FRSQ in Quebec, we did that in a variety 
of initiatives.
I can tell you that we’re not talking here about the 
protection of the intellectual property of a specific com-
pany. We’re talking about areas at the pre-competitive 
level, where research benefits everyone. It benefits the 
public sector. It benefits Canadians, and of course it also 
benefits  the  private  sector.  That’s  what  we  want,  isn’t 
it? We want the private sector to invest more. We don’t 
want to see them investing outside Canada. On the con-
trary, we want them to come back and invest in Canada 
so that we can actually gain economically from R and D 
investments.
I think we have a role to play in helping them do their 
job and doing our job better. It’s our mandate. It’s in the act.
Mr. Colin Carrie:  Dr. Prigent, your résumé speaks 
for itself, and I don’t think anybody at the table would 
dispute your immense body of experience. We do want 
to encourage more people in the private sector to become 
involved and help better communicate and work with 
governments, because at the end of the day, as we were 
saying, we want greater commercialization, innovation, 
research jobs, those spinoffs to our economy.
I was wondering if you could explain for the commit-
tee how you think your experiences qualify you for the 
role, and give us some thoughts on where you think the 
CIHR needs to go to position Canada globally, given the 
context Dr. Beaudet was discussing.
Dr.  Bernard  Prigent:  I  think  one  of  the  specific 
things that I will bring to CIHR is the experience that 
I’ve acquired working in various provinces, where that 
research for the right interface between public and pri-
vate has been set in motion.
If you look at Quebec, if you look at British Colum-
bia, if you look at Ontario, there is a series of initiatives 
at the provincial level that has encouraged and fostered 
innovative  partnerships.  We’ve  talked  about  the  cre-
ation of a consortium, which is at the pre-competitive 
level. In British Columbia, there has been the launch of 
not only the CDRD, the Centre for Drug Research and 
Development, but your government has launched cen-
tres of excellence for commercialization and research. 
Many companies have embraced those initiatives, and I 
think these are lessons, these are early days. But I think 
as an individual who is working and immersed in some 
of those initiatives, there is some experience that I can 
bring back to CIHR. CIHR is trying to develop an agenda 
to force the relationship with the private sector. 
The other areas where clearly I’ll be able to provide in-
sight is around the reinforcement of the clinical research 
capability, or, even more so, as was mentioned, the pa-
tient-centred outcome initiative, which is much broader 
than the clinical development of drugs, if you like. There 
are many elements where I think my expertise can en-
rich the thought process and the thinking among the 
members and the leaders of that initiative.
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goes beyond my current appointment is my background 
in global health. I know that CIHR is looking strategic-
ally at partnering around the world with global charities 
and other governments to address global health. I’m ex-
tremely convinced that a closer collaboration with the 
private sector can bring solutions to the health of many 
people in need, in Canada and beyond.
The Chair:  Thank you, Mr. Prigent.
Ms. Murray.
Ms. Joyce Murray (Vancouver Quadra, Liberal 
Party):   Thanks for being here to speak with us today. 
Like other intervenors, I wouldn’t question Dr. Prigent’s 
integrity or his understanding of conflict of interest. I 
acknowledge that pharmaceutical products have an im-
portant role in health care, as does commercialization. 
But here’s my concern: we’re struggling with our health 
care system across the country. We have a demographic 
that’s going to put more pressure on the system, and we 
know we need a new paradigm. We also know that phar-
maceuticals contribute to one out of nine emergency vis-
its to Vancouver General Hospital, and that those visits 
are more likely to result in admissions and longer hospi-
tal stays. […]
What we’re looking for is more in the way of a whole-
person  approach,  social  factors,  and  collaborative  ap-
proaches to disease prevention. 
When I look at the doctor’s résumé, I see that in 1981 
he completed GP training; from 1981 to 1983, he worked 
on a small island in western Samoa and then in New Zea-
land; and then for the next 25 years he was in the employ 
of the pharmaceutical industry. I guess you could say if 
you only have a hammer, every problem looks like a nail. 
Dr. Prigent brings a strong pharmaceutical bias to what 
should be a strategic direction in this council. […] 
I’d like Dr. Prigent to be able to respond to that bias. […]
Dr.  Bernard  Prigent:  The  work  in  the  pharma-
ceuticals  touches  on  global  health  issues.  I’ve  worked 
in pharma in sub-Saharan Africa, and I’m still involved 
with my former Pfizer colleagues in some malaria pro-
grams.  The  work  with  pharma  doesn’t  mean  that  the 
global health perspective that I had in the initial stages 
of my career has disappeared. I was involved in setting 
up a chronic disease management in respiratory medi-
cine in Africa. I collaborated with U.K. physicians and 
with African physicians. I believe I have maintained my 
original perspective. It has been strongly enriched by 
methodological learnings that I’ve acquired through the 
years. They are fundamental to the development of new 
technologies. You cannot develop technologies without 
looking at methodologies, and these methodologies will 
inform the work that we mean to establish with the aca-
demic communities. 
I take your point, but I believe that I have been able to 
maintain, through my activities and across therapeutic 
areas, a strong focus on health.
Ms.  Joyce  Murray:  But  that  was  always  within  a 
certain context. Your employers were large pharmaceut-
ical companies and the solutions were pharmaceutical 
solutions.
Dr.  Bernard  Prigent:  Indeed,  but  you  mentioned 
prevention, and there are a lot of prevention activities 
that reside in pharma. I have contributed to the study of 
preventive measures in a whole range of settings, with 
a  pharma  perspective.  The  fact  that  you’re  looking  at 
something from a pharma perspective doesn’t stop you 
from looking at issues in a holistic way and extracting 
lessons that could benefit CIHR.
The Chair:   You still have a bit more time, Ms. Murray.
Ms. Joyce Murray:  I’d like to ask the same question 
to Monsieur Beaudet. The governing council is talking 
about direction and strategy. We have one support let-
ter for this appointment and a number of others against. 
Doesn’t a whole career in the pharmaceutical industry 
bring a pharmaceutical bias to what should be a neutral 
approach?
Dr. Alain Beaudet:  The letter of support you have is 
a letter of support by the governing council, signed by all 
members.
Ms. Joyce Murray:  It’s the research-based pharma-
ceutical companies that are supporting it.
Dr. Alain Beaudet:  Perhaps the other letter was not 
distributed. There was a letter written to this commit-
tee, I think, sent to you on behalf of all members of the 
governing council.
The Chair:  They should all have a copy of it. If not, 
we’ll make sure they do.
Dr. Alain Beaudet:  Thank you.
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alysis, what was glaringly missing in terms of expertise 
on the council—because we do have experts in public 
health,  experts  in  global  health,  experts  in  basic  re-
search, experts in applied research, and experts in health 
policy—were experts in commercialization, innovation, 
and development of pharmacology. So I think we are fill-
ing a gap that was identified by council members, and 
I must say that, unanimously, members of council have 
approved  of  the  nomination  and  thanked  the  govern-
ment for listening to their request to provide someone 
who could fill that gap.
The Chair:  Thank you, Mr. Beaudet.
Now we’ll go to Dr. Carrie—or I’m sorry, Mrs. David-
son, instead. 
Mrs. Patricia Davidson (Sarnia—Lambton, Con-
servative Party of Canada):  Thanks, Madam Chair.
And thanks very much to both of you for being here 
with us this afternoon.
We’re hearing different, conflicting stories here. We’re 
talking about all these letters of displeasure, and so on. 
I received four letters of displeasure and one of support, 
and now you’re telling me there is another one that hasn’t 
been circulated. So in my mind, it really isn’t heavily 
weighted here.
Then there’s something else you just said, Dr. Beau-
det, that it was a unanimous decision by the council.
Dr. Alain Beaudet:  If I may, council unanimously 
approved  the  nomination  of  Mr.  Prigent.  It  was  wel-
comed unanimously by council as fulfilling a need.
Mrs.  Patricia  Davidson:  Thank  you  very  much. 
I am glad we’ve made that point clear. There has been 
some suggestion that perhaps it wasn’t unanimous, so 
I’m glad to hear you clarify that position.
I think one of the other things we’ve talked about on 
and off over many years is the fact that there needs to 
be better rapport and a better working relationship be-
tween  the  public  and  the  private  sector.  We  all  know 
that health research in science and technology is an ex-
tremely important area. But it’s not only important for 
the private sector; it’s important for the public sector too. 
To see both sides represented, I think there needs to be 
that collaboration and the input.
Can  you  tell  me,  what  are  CIHR’s  current  priority 
areas, and how will the appointment of Dr. Prigent help 
you work towards that? 
Dr. Alain Beaudet:  Certainly. Actually, I can even 
recommend excellent reading, which is the strategic plan 
of CIHR that was just launched a few weeks ago, where 
our priorities are very clearly outlined.
Without going into a large presentation of our stra-
tegic plan, I’ll just insist on impartiality and excellence 
in what we fund, based on excellence, and focusing on 
excellence and competitiveness internationally, a few se-
lect but very important health research priorities based 
on the needs of Canadians, which includes better sup-
port for patient-oriented research, including clinical re-
search; better support for research on our health care 
system and improving the sustainability of our health 
care  system;  better  support  of  research  on  aboriginal 
health issues and other vulnerable populations; support 
for chronic diseases and mental health, which, as you 
know, are major issues in our society and are only grow-
ing with the aging of the population; and further support 
of research into emerging threats. As you know, some 
of these emerging threats are infectious in nature—we 
are living it right now—but we can foresee more of these 
threats  that  are,  for  instance,  brought  in  by  climate 
change.
Those are the five major priorities of CIHR for the 
next five years. Quite clearly, I can see how critical Dr. 
Prigent’s expertise in clinical research will be in help-
ing  us  to  implement  our  priority  on  patient-oriented 
research strategy, how his superb expertise in research 
management will help us with our strategy on improving 
our health care system and the translation of the results 
of health research into better health care and health out-
comes for Canadians. I can see how his expertise with 
global health will help us respond to the priorities on vul-
nerable populations, on aboriginal health issues, which, 
as you know, are very similar to the ones in developing 
countries, but also on emerging threats, particularly in-
fection. And finally, Dr. Prigent has, as you saw, a wealth 
of expertise on a number of chronic diseases, which is 
the last focus in our strategic plan. 
So I feel, actually, that he’s exceptionally qualified to 
help us implement these different priorities during the 
next five years.
[1730 pm] Mrs. Patricia Davidson:  Thank you.
The Chair:  We’re pretty well finished now, Ms. David-
son. I’m sorry about that.
I want to thank both of you very much, Mr. Prigent 
and  Mr.  Beaudet,  for  coming  today.  You’ve  been  very 
helpful and very gracious. Clearly, the expertise before 
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ada. We welcome your input, Mr. Prigent, into the many 
very vital parts you will be serving in your appointment. 
Thank you for coming today.
The meeting is adjourned.
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